MedTrace Logo

Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab

NCT07510724 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 240

Last updated 2026-04-03

No results posted yet for this study

Summary

The ReWoLuTe study (IKF091) is a prospective, multi-center, observational cohort study conducted in Germany and Austria to collect real-world data on the use of Tislelizumab-based therapies in patients with lung cancer. The study aims to evaluate the overall survival, treatment patterns, safety, and health-related quality of life of patients receiving Tislelizumab in everyday clinical practice.

Conditions

  • Small Cell Lung Cancer (SCLC)
  • Non-Small Cell Lung Cancer (NSCLC)
  • Lung Cancer (Diagnosis)

Sponsors & Collaborators

  • BeOne Medicines

    collaborator INDUSTRY

  • Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

    lead OTHER

Principal Investigators

  • Raoul De Jonge, Dr. · Universitätsklinikum St. Pölten - Lilienfeld, Österreich

  • Akin Atmaca, PD Dr. med. · Krankenhaus Nordwest, Frankfurt, Deutschland

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-23
Primary Completion
2032-12-23
Completion
2033-01-23

Countries

  • Austria
  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07510724 on ClinicalTrials.gov